| The adenovirus type 5 E1B-55K oncoprotein is a highly active shuttle protein and shuttling is independent of E4orf6, p53 and Mdm2. | None |
| Expression of mdm-2 oncoprotein in the primary and metastatic sites of mammary tumor (GI-101) implanted athymic nude mice. | None |
| Cloning, sequence analysis and expression of the cDNAs encoding the canine and equine homologues of the mouse double minute 2 (mdm2) proto-oncogene. | None |
| MDM2 oncogene as a novel target for human cancer therapy. | None |
| Sequence-specific 1H, 15N, and 13C assignment of the N-terminal domain of the human oncoprotein MDM2 that binds to p53. | None |
| Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. | None |
| A modified p53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent. | None |
| Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. | None |
| Stabilization of the MDM2 oncoprotein by mutant p53. | None |
| The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants. | None |
| Preferential expression of Mdm2 oncogene during the development of neural crest and its derivatives in mouse early embryogenesis. | None |
| Fragments of human oncoprotein MDM2 reveal variable distribution within and on cultivated human hepatoma cells. | None |
| The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. | None |
| Genetic analysis of the human oncoprotein MDM2 in benign and malignant tumors of the salivary gland. | None |
| Function and dysfunction of the human oncoprotein MDM2. | None |
| Normal cells may induce full-length MDM2 in response to oncogenic challenges to protect against premature cell cycle progression. MDM2 is regulated by p53 especially durnig embryogenesis where MDM2 function is inhibited. | None |
| Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes. | None |
| MDM2 has been characterized as a protein that binds to and facilitates degradation of the tumor suppressor p53. Splice variants of MDM2 transcripts have been identified in both tumors and normal tissues. | None |
| The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. | None |
| Characterization of two peptide epitopes on Mdm2 oncoprotein that affect p53 degradation. | None |